Want to see CARL full AI Analyst Report?
CARL Stock Chart & Stats
$10.98
--
Market closed
$10.98
--
Day’s Range― - ―
52-Week Range$8.50 - $17.19
Previous CloseN/A
VolumeN/A
Average Volume (3M)146.23K
Market Cap
$299.58M
Enterprise Value$163.00
Total Cash (Recent Filing)$97.02M
Total Debt (Recent Filing)$17.25M
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Aug 05, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.44
Shares Outstanding27,184,933
10 Day Avg. Volume156,264
30 Day Avg. Volume146,234
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)1.78
Price to Sales (P/S)3.48
P/FCF Ratio-5.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$18.40Price Target Upside67.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.48
Revenue Forecast (FY)$74.82M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth & Surgeon AdoptionSustained double‑digit top‑line growth and rapid surgeon adoption signal expanding market penetration and accelerating clinical uptake. A growing user base reduces customer acquisition friction, supports recurring procedure volume, and underpins durable revenue scale as the company commercializes its platform.
High Gross Margins & Production EfficiencyMid‑to‑high‑70s gross margins plus markedly shorter lead times indicate strong unit economics and scalable production. Persistent high margins from a customized implant model support long‑term profitability potential as volumes scale and fixed costs are leveraged across production.
Solid Liquidity And Modest LeverageNear‑term runway is supported by roughly $97M of cash and limited draws on its debt facility, providing flexibility to invest in commercialization and R&D. Modest outstanding leverage reduces refinancing pressure while management scales toward adjusted EBITDA improvement.
Bears Say
Persistent Cash BurnConsistent and rising negative operating cash flow shows the business still consumes material cash to grow. Continued cash burn requires external financing or sustained margin/operational improvement to avoid dilution or debt dependence before reaching cash‑flow breakeven.
Widening GAAP Losses & Negative Adjusted EBITDADespite revenue expansion, losses and negative adjusted EBITDA widened, indicating operating leverage has not yet absorbed scaling costs. If losses persist, it lengthens the path to profitability and increases dependence on capital markets even as unit economics improve.
Rising Operating ExpensesRapid increases in R&D, sales & marketing, and G&A reflect aggressive scaling but raise structural fixed costs. If revenue growth slows or margins compress from product mix, elevated expense levels could delay sustained profitability and require ongoing efficiency execution.
Carlsmed, Inc. News
CARL FAQ
What was Carlsmed, Inc.’s price range in the past 12 months?
Carlsmed, Inc. lowest stock price was $8.50 and its highest was $17.19 in the past 12 months.
What is Carlsmed, Inc.’s market cap?
Carlsmed, Inc.’s market cap is $299.58M.
When is Carlsmed, Inc.’s upcoming earnings report date?
Carlsmed, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 12 days.
How were Carlsmed, Inc.’s earnings last quarter?
Carlsmed, Inc. released its earnings results on May 05, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.38 by $0.06.
Is Carlsmed, Inc. overvalued?
According to Wall Street analysts Carlsmed, Inc.’s price is currently Undervalued.
Does Carlsmed, Inc. pay dividends?
Carlsmed, Inc. does not currently pay dividends.
What is Carlsmed, Inc.’s EPS estimate?
Carlsmed, Inc.’s EPS estimate is -0.4.
How many shares outstanding does Carlsmed, Inc. have?
Carlsmed, Inc. has 27,184,933 shares outstanding.
What happened to Carlsmed, Inc.’s price movement after its last earnings report?
Carlsmed, Inc. reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.38. Following the earnings report the stock price went up 10.314%.
Which hedge fund is a major shareholder of Carlsmed, Inc.?
Currently, no hedge funds are holding shares in CARL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Carlsmed, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.40 (67.58% Upside)
$18.40 (67.58% Upside)
Blogger Sentiment
Bullish
CARL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 23.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
105.36%
Trailing 12-Months
Company Description
Carlsmed, Inc.
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
CARL Stock 12 Month Forecast
Average Price Target
$18.40
▲(67.58% Upside)
Technical Analysis
Ownership Overview
71.74% Insiders
6.15% Mutual Funds
7.87% Other Institutional Investors
11.87% Public Companies and
Individual Investors